Weekly Investment Analysts’ Ratings Updates for Enanta Pharmaceuticals (ENTA)

A number of firms have modified their ratings and price targets on shares of Enanta Pharmaceuticals (NASDAQ: ENTA) recently:

  • 2/12/2018 – Enanta Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $82.00 price target on the stock. According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
  • 2/10/2018 – Enanta Pharmaceuticals was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 2/8/2018 – Enanta Pharmaceuticals had its price target raised by analysts at Royal Bank of Canada to $78.00. They now have a “sector perform” rating on the stock.
  • 2/8/2018 – Enanta Pharmaceuticals was downgraded by analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating.
  • 1/30/2018 – Enanta Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
  • 1/2/2018 – Enanta Pharmaceuticals was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $54.00 price target on the stock.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) opened at $78.65 on Wednesday. Enanta Pharmaceuticals Inc has a 52 week low of $27.24 and a 52 week high of $95.91. The company has a market capitalization of $1,470.39, a PE ratio of 45.46 and a beta of 1.04.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing analysts’ consensus estimates of $2.13 by ($0.27). Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. The firm had revenue of $75.93 million during the quarter, compared to analysts’ expectations of $73.80 million. During the same quarter last year, the firm earned ($0.09) EPS. The business’s revenue for the quarter was up 491.3% compared to the same quarter last year. sell-side analysts forecast that Enanta Pharmaceuticals Inc will post 0.86 earnings per share for the current fiscal year.

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply